Vaishali Pharma Limited Stock Price Today (NSE: VAISHALI)
Fundamental Score
Vaishali Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vaishali Pharma Limited share price today is ₹8.68, down 3.77% on NSE/BSE as of 16 September 2026. Vaishali Pharma Limited (VAISHALI) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹56.62 (Cr). The 52-week high for VAISHALI share price is ₹12.70 and the 52-week low is ₹4.75. At a P/E ratio of 25.53x, VAISHALI is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 6.21% and a debt-to-equity ratio of 0.27.
Vaishali Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Vaishali Pharma Limited share price chart: 1.58% return over the past month. 52-week high ₹12.70, 52-week low ₹4.75.
Vaishali Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹8.70 | ₹9.03 | ₹8.42 | ₹8.68 | 1.43L (Cr) | |
| ₹9.25 | ₹9.25 | ₹8.81 | ₹9.02 | 3.57L (Cr) | |
| ₹8.22 | ₹9.42 | ₹8.22 | ₹8.77 | 3.93L (Cr) | |
| ₹8.30 | ₹8.69 | ₹8.01 | ₹8.57 | 2.05L (Cr) | |
| ₹8.47 | ₹8.47 | ₹8.05 | ₹8.14 | 1.66L (Cr) | |
| ₹8.54 | ₹8.56 | ₹8.30 | ₹8.34 | 71.38K (Cr) | |
| ₹8.53 | ₹8.53 | ₹8.21 | ₹8.37 | 91.77K (Cr) | |
| ₹8.44 | ₹8.54 | ₹8.16 | ₹8.32 | 68.89K (Cr) | |
| ₹8.25 | ₹8.48 | ₹8.02 | ₹8.36 | 92.14K (Cr) | |
| ₹8.03 | ₹8.35 | ₹7.81 | ₹8.06 | 80.52K (Cr) |
Vaishali Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹8.01 | ₹9.42 | ₹7.81 | ₹8.68 | +8.36% | |
| ₹7.70 | ₹8.85 | ₹7.35 | ₹8.06 | +4.68% | |
| ₹7.20 | ₹8.18 | ₹6.96 | ₹7.35 | +2.08% | |
| ₹7.29 | ₹7.89 | ₹6.81 | ₹7.21 | -1.10% | |
| ₹7.76 | ₹7.90 | ₹6.72 | ₹7.05 | -9.15% | |
| ₹5.00 | ₹9.30 | ₹5.00 | ₹7.61 | +52.20% | |
| ₹7.19 | ₹7.19 | ₹4.75 | ₹4.88 | -32.13% | |
| ₹8.05 | ₹8.30 | ₹6.81 | ₹6.97 | -13.42% | |
| ₹8.83 | ₹9.80 | ₹7.93 | ₹7.97 | -9.74% | |
| ₹8.85 | ₹9.78 | ₹7.75 | ₹8.62 | -2.60% | |
| ₹10.19 | ₹10.27 | ₹8.51 | ₹8.79 | -13.74% | |
| ₹11.55 | ₹11.88 | ₹9.00 | ₹10.04 | -13.07% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vaishali Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vaishali Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VAISHALI across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 25.53 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (20.86%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (15.13% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (31.82% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.27)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 2.25)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Below-Average Return on Equity (6.21%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Weak Earnings Growth (-20.22% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vaishali Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Vaishali Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
7.3/100 | ₹8.68₹9 | ₹56.62₹56.62 | 25.53Average 25.5 Average | 6.21%Poor 6.21% Poor | 10.15%Average 10.15% Average | 0.27Excellent 0.3 Excellent | 31.82%Excellent 31.82% Excellent | 15.13%Excellent 15.13% Excellent | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Vaishali Pharma Limited PE Ratio History
Historical price-to-earnings ratio for VAISHALI — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.06 | ₹17.49 | 273.3x |
| FY 2023 | ₹0.59 | ₹18.20 | 30.8x |
| FY 2022 | ₹0.38 | ₹13.87 | 36.3x |
| FY 2021 | ₹0.10 | ₹3.58 | 36.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Vaishali Pharma Limited Quarterly Performance
Latest quarterly metrics for VAISHALI — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-3.60%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
20.86%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.13%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
31.82%
Compounded annual net profit growth over 5 years
Vaishali Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VAISHALI — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Vaishali Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Vaishali Pharma Limited (VAISHALI) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Vaishali Pharma Limited
About VAISHALI (Vaishali Pharma Limited)
Vaishali Pharma Ltd is a dynamic pharmaceutical company committed to developing, manufacturing, and distributing a wide range of high-quality pharmaceutical products. Focused on im...proving patient health and well-being, Vaishali operates with a dedication to innovation, scientific rigor, and ethical practices. The company strives to meet the evolving healthcare needs of communities globally by offering a comprehensive portfolio of medications. Vaishali Pharma is dedicated to creating affordable and accessible solutions for various medical conditions. Through continuous research and development, state-of-the-art manufacturing facilities, and a strong commitment to quality, Vaishali Pharma aspires to be a trusted partner in healthcare. Vaishali Pharma's product line encompasses an extensive array of therapeutic categories designed to address a multitude of health concerns. The company produces and markets essential drugs covering areas such as infectious diseases, pain management, respiratory illnesses, cardiovascular health, and metabolic disorders. Vaishali’s broad portfolio includes both generic medications and specialized formulations, ensuring a wide reach and accessibility for patients. Committed to maintaining the highest standards, Vaishali Pharma adheres to stringent quality control measures throughout the production process, from raw material sourcing to final product packaging. This commitment guarantees that all products are safe, effective, and meet the rigorous requirements of regulatory bodies. Vaishali Pharma's global reach extends to numerous markets, allowing it to make a significant impact on healthcare systems around the world. The company is dedicated to expanding its presence through strategic partnerships, innovative product development, and a steadfast focus on customer satisfaction. Vaishali emphasizes strong relationships with healthcare professionals, distributors, and regulatory agencies to ensure its medications reach those who need them most. By fostering a culture of excellence and continuous improvement, Vaishali Pharma strives to remain at the forefront of the pharmaceutical industry, constantly seeking new ways to improve patient outcomes and contribute to a healthier future.
Company Details
Key Leadership
VAISHALI Share Price: Frequently Asked Questions
What is the current share price of Vaishali Pharma Limited?
Vaishali Pharma Limited (VAISHALI) trades at ₹8.68 on NSE. Market cap ₹56.62 (Cr). Educational data only.
What is the P/E ratio of Vaishali Pharma Limited?
Vaishali Pharma Limited has a P/E of 25.53x vs industry average 34.89x.
What is the Bull Run score for Vaishali Pharma Limited?
Vaishali Pharma Limited has a Bull Run score of 7.3/100 based on 25+ financial parameters.
Does Vaishali Pharma Limited pay dividends?
Vaishali Pharma Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Vaishali Pharma Limited?
Vaishali Pharma Limited has ROE of 6.21%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vaishali Pharma Limited?
Vaishali Pharma Limited has debt-to-equity of 0.27.
Is Vaishali Pharma Limited a good investment?
Bull Run gives Vaishali Pharma Limited a score of 7.3/100. This is not investment advice — consult a SEBI-registered advisor.